INDV vs. KRYS, VRNA, CYTK, ELAN, PTCT, ADMA, ZLAB, RNA, OGN, and ACLX
Should you be buying Indivior stock or one of its competitors? The main competitors of Indivior include Krystal Biotech (KRYS), Verona Pharma (VRNA), Cytokinetics (CYTK), Elanco Animal Health (ELAN), PTC Therapeutics (PTCT), ADMA Biologics (ADMA), Zai Lab (ZLAB), Avidity Biosciences (RNA), Organon & Co. (OGN), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry.
Indivior vs.
Indivior (NASDAQ:INDV) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment.
60.3% of Indivior shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 14.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Indivior has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.
Indivior presently has a consensus price target of $15.00, indicating a potential upside of 48.51%. Krystal Biotech has a consensus price target of $220.00, indicating a potential upside of 13.15%. Given Indivior's stronger consensus rating and higher probable upside, analysts clearly believe Indivior is more favorable than Krystal Biotech.
Krystal Biotech has a net margin of 30.69% compared to Indivior's net margin of -3.96%. Krystal Biotech's return on equity of 11.41% beat Indivior's return on equity.
In the previous week, Krystal Biotech had 12 more articles in the media than Indivior. MarketBeat recorded 13 mentions for Krystal Biotech and 1 mentions for Indivior. Indivior's average media sentiment score of 1.88 beat Krystal Biotech's score of 1.16 indicating that Indivior is being referred to more favorably in the media.
Krystal Biotech received 284 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 67.66% of users gave Krystal Biotech an outperform vote.
Krystal Biotech has lower revenue, but higher earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.
Summary
Krystal Biotech beats Indivior on 12 of the 18 factors compared between the two stocks.
Get Indivior News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indivior Competitors List
Related Companies and Tools
This page (NASDAQ:INDV) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy INDV Stock Free INDV Stock Alerts